Apyx Medical (NASDAQ:APYX) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Apyx Medical (NASDAQ:APYX) announced its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06, FiscalAI reports. The company had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.78 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%.

Here are the key takeaways from Apyx Medical’s conference call:

• Apyx reported strong top-line growth in Q1 — $12.5M total revenue, up 32% year-over-year, driven by a 36% increase in Surgical Aesthetics sales to $10.7M largely from AYON system and consumable handpiece demand.
• Management says AYON is in an early but fast ramp following its Sept 2025 launch, and expects FDA 510(k) clearance for power-assisted liposuction this quarter with a limited early-adopter commercial rollout planned.
• The company raised 2026 revenue guidance to $59M–$60M, projects gross margins of ~62%–63% and capped operating expenses at $45M, reflecting improved profitability trends (Q1 GAAP net loss narrowed vs. prior year).
• International momentum is building after recent approvals (notably South Korea), with initial generator and handpiece demand exceeding expectations and plans to register AYON in major markets over time.
• Despite improvements, Apyx remains unprofitable (Q1 net loss attributable to stockholders was $2.1M), expects OEM revenue to decline year-over-year, and has a stated cash runway through 2027 with $31.1M in cash as of March 31, 2026.

Apyx Medical Price Performance

Shares of APYX traded up $0.11 during mid-day trading on Friday, reaching $3.67. The stock had a trading volume of 256,333 shares, compared to its average volume of 150,327. The firm has a market cap of $153.52 million, a price-to-earnings ratio of -13.59 and a beta of 1.35. Apyx Medical has a 12 month low of $1.08 and a 12 month high of $4.50. The business has a fifty day moving average of $3.63 and a 200 day moving average of $3.70. The company has a debt-to-equity ratio of 2.35, a quick ratio of 4.26 and a current ratio of 5.00.

Wall Street Analyst Weigh In

APYX has been the subject of a number of recent analyst reports. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Wednesday, March 11th. Craig Hallum upped their price target on shares of Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Friday, March 27th. Finally, Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

More Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q1 results beat expectations: revenue of $12.49M vs. ~$10.8M consensus and EPS loss of ($0.05) vs. ($0.11) expected — the top?line and EPS beats are the immediate catalyst supporting the stock. GlobeNewswire Q1 Release
• Positive Sentiment: Management raised FY?2026 revenue guidance to $59.0M–$60.0M, citing accelerating demand for the AYON Body Contouring System — this guidance lift (above prior consensus) is a near?term growth signal. Seeking Alpha: Revenue Outlook Raised
• Neutral Sentiment: Management commentary and the earnings call/transcript provide details on AYON adoption and commercial cadence; investors will watch execution and cadence updates in coming quarters. Yahoo Earnings Transcript
• Neutral Sentiment: Media note: Apyx also received an industry honor mentioned alongside other companies (limited direct financial impact but supports brand/PR). MSN: Honor Mention
• Negative Sentiment: Company remains unprofitable (negative net margin ~?21% and negative ROE) and carries leverage (debt/equity ~2.35); consensus still forecasts negative FY?2026 EPS — profitability and cash?flow improvement remain key risks for the stock. Zacks Q1 Coverage

Hedge Funds Weigh In On Apyx Medical

Several hedge funds have recently modified their holdings of APYX. Nantahala Capital Management LLC lifted its holdings in shares of Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after buying an additional 80,000 shares in the last quarter. Osaic Holdings Inc. purchased a new position in shares of Apyx Medical in the second quarter worth $50,000. Vanguard Group Inc. lifted its holdings in shares of Apyx Medical by 3.6% in the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after buying an additional 53,175 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Apyx Medical in the third quarter worth $59,000. Finally, Citadel Advisors LLC purchased a new position in shares of Apyx Medical in the third quarter worth $28,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.